Previous event: Chemotherapy and immunotherapy updates in colorectal cancer
Event details
- Date: Tuesday 4 November
- Time: 2-3.15pm
- Who's it for: Colorectal clinical nurse specialists, endoscopists and specialist screening practitioners
- Where: online via Zoom
The session, led by Professor Mark Saunders, Consultant Clinical Oncologist at The Christie NHS Foundation Trust, will provide a brief history of the evolution of chemotherapy over the last 25 years and concentrate on the management of patients with chemotherapy including genetic mutation targeted therapies and immunotherapy.
You’ll also have the opportunity to participate in a Q&A session at the end of the event.
Learning outcomes:
- Gold standard lines of chemotherapy for patients with metastatic colorectal cancer
- What mutations should be targeted and their outcomes
- Immunotherapy for dMMR/MSI-H metastatic colorectal cancer
Speaker bio
Professor Mark Saunders, MBBS, MRCP, FRCR, PhD, received his medical degree from Charing Cross Hospital, London, UK, in 1986. He spent 5 years working in general medicine before specialising in oncology, first at the Churchill Hospital in Oxford and later at The Christie in Manchester where was made a consultant at in 1999.
His main area of interest is running all phases of chemotherapy and radiotherapy clinical trials evaluating novel agents with associated response / toxicity biomarkers and radiology (colorectal cancer, anal cancer, and pseudomyxoma). He has written a series of protocols for clinical trials that have been funded, completed and published. He also chairs or is a member of a number of Trial Management Groups (TMGs) and Data Monitoring Committees (DMCs). Professor Saunders has been a member of number of NCRN and CRUK committees and previously chaired the Northern Cancer Drug Fund (CDF) committee. He works closely with Bowel Cancer UK, a charity dedicated to raising awareness of bowel cancer, improving the quality of life of those affected and, ultimately, reducing deaths from bowel cancer.
